BMY Sep 2024 60.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:25PM EDT. Market open.
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0700 |
| Ask | 0.0800 |
| Strike | 60.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.0700 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 923 |
ZacksThe Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
- Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GlobeNewswireEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
© 2024 Yahoo. All rights reserved.